-
Three First-Line Strategies for EGFR-Mutant NSCLC: How to Choose the Right One?
Clinicians and researchers continue to seek targeted treatment strategies for EGFR-mutant non-small cell lung cancer (NSCLC), with an increasing number of clinical trials evaluating combination therapies. Two recent high-profile studies, the FLAURA-2 and MARIPOSA trials, have led to the FDA approval of new first-line treatment options for EGFR-mutant NSCLC in 2024.
-
Honoring Dr. Abdullah Tarik Aslan and His Research on Antibiotic-Associated Nephrotoxicity
Dr. Abdullah Tarik Aslan, alongside his colleagues, has led an important multinational, multicenter cohort study investigating the risk of acute kidney injury (AKI) in patients receiving piperacillin-tazobactam (TZP) with either vancomycin (VAN) or teicoplanin (TEI).
-
Unlocking the Potential of Antibody-Drug Conjugates in Pancreaticobiliary Cancers: Mechanisms and Key Selection Criteria
Mechanism of ADCs and Antigenic Targets ADCs function through a three-component system, comprising a monoclonal antibody (mAb) targeting a tumor-specific antigen, a cytotoxic payload, and a linker that facilitates payload…
-
Breaking New Ground in GEP-NET Treatment: Everolimus Plus Lanreotide Doubles Progression-Free Survival in STARTER-NET Trial
Presented by Dr. Susumu Hijioka at the ASCO Gastrointestinal Cancers Symposium, the STARTER-NET trial explores new frontiers in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are…
-
ASCO GI Highlights! A Breakthrough for Cadonilimab in Gastrointestinal Cancers
From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) was held in San Francisco, USA. At this prestigious event, Cadonilimab, the world’s first bispecific antibody developed in China, achieved multiple breakthroughs in the treatment of gastrointestinal cancers.Several research teams, including Professors Jing Huang and Wang Qu…
-
ASCO GI 2025 | CD47 Blockade Combination Therapy Shows Anti-Tumor Potential in Previously Treated HER2-Positive Gastric Cancer
The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. During the conference, numerous high-impact research findings were presented, including the ASPEN-06 study (Abstract #332), a global Phase II/III randomized trial evaluating the efficacy of evorpact (Evo) in combination with trastuzumab, ramucirumab, and paclitaxel (TRP) in patients…
-
ASCO GI 2025 | Dr. Xiufeng Liu’s In-Depth Analysis of CheckMate 9DW and CARES-310 Study Updates
The landscape of systemic therapy for hepatocellular carcinoma (HCC) has undergone a major transformation, shifting from single-agent targeted or immunotherapies to dual immune checkpoint inhibitors and immune-targeted combination regimens. The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), held on January 23, 2025, highlighted two pivotal studies—CheckMate 9DW and CARES-310—focusing on dual immunotherapy strategies for previously…
-
Dr. Xiangrui Meng: “VEGF-TKI + PD-1 Inhibitor + Chemotherapy” as a Potential New Treatment Option for PD-L1-Negative Advanced Gastric Cancer
In recent years, the emergence and breakthrough progress of multiple targeted and immunotherapy drugs, along with their combination regimens, have brought significant transformation to the systemic treatment of esophageal and gastric cancer. The field has evolved from monotherapy with targeted or immune agents to an era of dual or multi-immunotherapy combinations.
Connecting Medical Expertise through Media